A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 8,814 shares of ARCT stock, worth $149,573. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,814
Previous 9,646 8.63%
Holding current value
$149,573
Previous $234,000 12.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$18.08 - $25.38 $15,042 - $21,116
-832 Reduced 8.63%
8,814 $204,000
Q2 2024

Aug 12, 2024

BUY
$24.35 - $44.39 $170 - $310
7 Added 0.07%
9,646 $234,000
Q1 2024

May 09, 2024

SELL
$31.23 - $42.99 $13,772 - $18,958
-441 Reduced 4.38%
9,639 $325,000
Q4 2023

Feb 08, 2024

SELL
$17.71 - $32.97 $13,689 - $25,485
-773 Reduced 7.12%
10,080 $317,000
Q3 2023

Nov 07, 2023

BUY
$25.44 - $37.35 $15,416 - $22,634
606 Added 5.91%
10,853 $277,000
Q2 2023

Aug 09, 2023

SELL
$23.94 - $32.36 $157,549 - $212,961
-6,581 Reduced 39.11%
10,247 $293,000
Q1 2023

May 08, 2023

BUY
$14.72 - $23.97 $15,279 - $24,880
1,038 Added 6.57%
16,828 $403,000
Q4 2022

Feb 07, 2023

BUY
$14.14 - $23.06 $26,512 - $43,237
1,875 Added 13.47%
15,790 $267,000
Q2 2022

Aug 04, 2022

BUY
$12.26 - $31.17 $68,864 - $175,081
5,617 Added 67.69%
13,915 $219,000
Q1 2022

May 09, 2022

BUY
$17.64 - $39.57 $12,118 - $27,184
687 Added 9.03%
8,298 $224,000
Q4 2021

Feb 07, 2022

SELL
$34.2 - $47.56 $95,418 - $132,692
-2,790 Reduced 26.82%
7,611 $301,000
Q3 2021

Nov 04, 2021

BUY
$27.88 - $58.25 $7,527 - $15,727
270 Added 2.67%
10,401 $497,000
Q2 2021

Aug 06, 2021

BUY
$25.79 - $42.11 $261,278 - $426,616
10,131 New
10,131 $343,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $451M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.